Tigilanol tiglate

Scientific and clinical publications


De Ridder, T. et al. Use of the intratumoural Anticancer Drug Tigilanol Tiglate in Two Horses. Frontiers in Veterinary Science, 09 September, 2020

De Ridder TR et al. Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC -46). Journal of Veterinary Internal Medicine, June 2020.

Moses, R. L., et al. Novel epoxy-tiglianes stimulate skin keratinocyte wound healing responses and re-epithelialization via protein kinase C activation. Biochemical Pharmacology, May 2020

Hansen N et al. Progressive cutaneous viral pigmented plaques in three Hungarian Vizslas and the response of the lesions to topical tigilanol tiglate gel. Veterinary Medicine and Science; 2018

Panizza Benedict J. et al. Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intratumoral injection of tigilanol tiglate (EBC-46). EBioMedicine, December 2019

Miller J et al. Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors.. Frontiers in Veterinary Science, Volume 6, Article 106, April 2019

Barnett C, et al. Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate. Investigational New Drugs; April 2018

Boyle G, et al. Intra-lesional Injection of the Novel PKC Activator EBC-46 Rapidly Ablates Tumors in Mouse Models, PLOS ONE 2017, Vol 9, Issue 10, page number: e108887

Grant EL et al. Floral and reproductive biology of the medicinally significant rainforest tree, Fontainea picrosperma (Euphorbiaceae) Industrial Crops & Products 108 (2017) 416-422